{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:07:00Z","timestamp":1784002020660,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s10067-019-04508-2","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T18:03:38Z","timestamp":1553623418000},"page":"2109-2117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis"],"prefix":"10.1007","volume":"38","author":[{"given":"Samah Hamdy","family":"Elmedany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly Elsayed","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-6121","authenticated-orcid":false,"given":"Sahar Mahfouz Abdel","family":"Galil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"4508_CR1","first-page":"955","volume":"1","author":"J Giles","year":"2010","unstructured":"Giles J, Bathon JM (2010) Management of rheumatoid arthritis: synovitis. Rheumatology 1:955\u2013963","journal-title":"Rheumatology"},{"key":"4508_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","volume":"372","author":"P Emery","year":"2008","unstructured":"Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet 372:375\u2013382","journal-title":"Lancet"},{"key":"4508_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1136\/ard.2005.045062","volume":"65","author":"A Finckh","year":"2006","unstructured":"Finckh A, Simard JF, Gabay C, Guerne PA (2006) Evidence for differential acquired drug resistance to anti-tumor necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 65:746\u2013752","journal-title":"Ann Rheum Dis"},{"key":"4508_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/art.24463","volume":"61","author":"SM Pan Du","year":"2009","unstructured":"Du Pan SM, Dehler S, Ciurea A et al (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61:560\u2013568","journal-title":"Arthritis Rheum"},{"key":"4508_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/BOR.0b013e328337bd01","volume":"22","author":"MH Buch","year":"2010","unstructured":"Buch MH (2010) Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 22:321\u2013329","journal-title":"Curr Opin Rheumatol"},{"key":"4508_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13075-016-1179-7","volume":"18","author":"LR Harrold","year":"2016","unstructured":"Harrold LR, Reed GW, Solomon DH, Curtis JR et al (2016) Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry and Joel M. Kremer 5,6. Arthritis Res Ther 18:280","journal-title":"Arthritis Res Ther"},{"key":"4508_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/rheumatology\/kex060.079","volume":"56","author":"RJ Moots","year":"2017","unstructured":"Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, Donaldson F, Dimonaco S, Rubbert-Roth A, van Vollenhoven R, Genovese MC (2017) Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology 56:541\u2013549","journal-title":"Rheumatology"},{"key":"4508_CR8","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959\u20133964","journal-title":"Blood"},{"key":"4508_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double blind, placebo-controlled, randomized trial. Lancet 371:987\u2013997","journal-title":"Lancet"},{"key":"4508_CR10","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2006.068064","volume":"6","author":"N Nishimoto","year":"2007","unstructured":"Nishimoto N, Hashimoto J, Miyasaka N et al (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor\u2014evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 6:1162\u20131167","journal-title":"Ann Rheum Dis"},{"key":"4508_CR11","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2008.092866","volume":"68","author":"N Nishimoto","year":"2009","unstructured":"Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J (2009) Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68:1580\u20131584","journal-title":"Ann Rheum Dis"},{"key":"4508_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.immuni.2006.03.001","volume":"24","author":"J Bluestone","year":"2006","unstructured":"Bluestone J, St. Clair E, Turka L (2006) CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24:233\u2013238","journal-title":"Immunity"},{"key":"4508_CR13","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/art.21206","volume":"52","author":"RQ Cron","year":"2005","unstructured":"Cron RQ (2005) A signal achievement in the treatment of arthritis [editorial]. Arthritis Rheum 52:2229\u20132232","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4508_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40037","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear C, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA, Vasculitis Clinical Research Consortium (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol 69(4):846\u2013853","journal-title":"Arthritis Rheumatol"},{"key":"4508_CR15","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, M\u00e9nard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsk\u00fd J, Wolfe F, Hawker G (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4508_CR16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/2229-3485.71856","volume":"1","author":"TV Sakpal","year":"2010","unstructured":"Sakpal TV (2010) Sample size estimation in clinical trial. Perspect Clin Res 1(2):67\u201369","journal-title":"Perspect Clin Res"},{"issue":"1","key":"4508_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van\u2019t Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44\u201348","journal-title":"Arthritis Rheum"},{"key":"4508_CR18","doi-asserted-by":"publisher","unstructured":"Kubo S, Nakayamada S, Nakano K et al (2015) Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-207784","DOI":"10.1136\/annrheumdis-207784"},{"issue":"11","key":"4508_CR19","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/1756-185X.12845","volume":"19","author":"T Pascart","year":"2016","unstructured":"Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, Houvenagel E, Flipo RM (2016) Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicenter study. Int J Rheum Dis 19(11):1093\u20131102","journal-title":"Int J Rheum Dis"},{"key":"4508_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4137\/CMAMD.S4864","volume":"3","author":"G Jones","year":"2010","unstructured":"Jones G, Ding C (2010) Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 3:81\u201389","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"4508_CR21","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/rheumatology\/kev372","volume":"55","author":"C King-Konert","year":"2016","unstructured":"King-Konert C, von Hin\u00fcber U, Richter C et al (2016) ROUTINE\u2014a prospective, multicenter, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Rheumatology 55:624\u2013635","journal-title":"Rheumatology"},{"issue":"5","key":"4508_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2217\/ijr.10.52","volume":"5","author":"M Schiff","year":"2010","unstructured":"Schiff M, Poncet C, Le Bars M (2010) Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice. Int J Clin Rheumatol 5(5):581\u2013591","journal-title":"Int J Clin Rheumatol"},{"issue":"7","key":"4508_CR23","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1136\/ard.2010.140129","volume":"70","author":"HC Leffers","year":"2011","unstructured":"Leffers HC, Ostergaard M, Glintborg B, Krogh NS et al (2011) Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70(7):1216\u20131222","journal-title":"Ann Rheum Dis"},{"key":"4508_CR24","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s10067-014-2711-2","volume":"33","author":"S Hirabara","year":"2014","unstructured":"Hirabara S, Takahashi N, Fukaya N, Hiroyuki H et al (2014) Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies. Clin Rheumatol 33:1247\u20131254","journal-title":"Clin Rheumatol"},{"issue":"11","key":"4508_CR25","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis 67(11):1516\u20131523","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4508_CR26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/ard.2007.074773","volume":"67","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, Schiff M, Luggen M, Becker JC et al (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67(4):547\u2013554","journal-title":"Ann Rheum Dis"},{"key":"4508_CR27","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1136\/ard.2008.099218","volume":"68","author":"M Schiff","year":"2009","unstructured":"Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, Li T, Bahrt K, Kelly S, le Bars M, Genovese MC (2009) The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 68:1708\u20131714","journal-title":"Ann Rheum Dis"},{"key":"4508_CR28","first-page":"553","volume":"32","author":"R Westhovens","year":"2014","unstructured":"Westhovens R, Kremer JM, Emery P, Russell AS, Alten R, Barr\u00e9 E, Dougados M (2014) Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol 32:553\u2013562","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 10","key":"4508_CR29","first-page":"2550","volume":"68","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Morel J, Constantin A et al (2016) Long-term registry data in 4498 patients with rheumatoid arthritis indicate a similar safety but a different drug retention between abatacept, rituximab and tocilizumab. Arthr Rheumatol. 68(Suppl 10):2550\u20132553","journal-title":"Arthr Rheumatol."},{"issue":"Suppl 10","key":"4508_CR30","first-page":"3536","volume":"68","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Morel J, Constantin A et al (2016) Similar rates of death, serious infections, cancers, major cardiovascular events in patients treated with abatacept, rituximab and tocilizumab: long-term registry data in 4498 patients with rheumatoid arthritis. Arthr Rheumatol 68(Suppl 10):3536\u20133537","journal-title":"Arthr Rheumatol"},{"key":"4508_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC (2010) Comparison of TCZ monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88\u201396","journal-title":"Ann Rheum Dis"},{"key":"4508_CR32","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/ard.2008.101964","volume":"68","author":"E Choy","year":"2009","unstructured":"Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68:460\u2013469","journal-title":"Ann Rheum Dis"},{"key":"4508_CR33","first-page":"S783","volume":"58","author":"JM Kremer","year":"2008","unstructured":"Kremer JM, van Vollenhoven RF, Ridley DJ et al (2008) Relationship between patient characteristics and the development of serious infections in patients receiving tocilizumab: results from long-term extension studies with a follow-up duration of 1.5 years. Arthritis Rheum 58:S783\u2013S784","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04508-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04508-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04508-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T05:09:15Z","timestamp":1721106555000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04508-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["4508"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04508-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"assertion":[{"value":"22 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Our study was approved according to the local ethical committee inside all hospitals that participated in this study. All selected patients have given written informed consents, before being enrolled in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}